Abstracts tagged "clinical trials and glucocorticoids"

Abstract Number: 3141 • 2016 ACR/ARHP Annual Meeting
Development of a Glucocorticoid Toxicity Index Using Multi-Criteria Decision Analysis
Eli Miloslavsky¹, Raymond P. Naden², Johannes WJ Bijlsma³, Paul Brogan⁴, Sherwood Brown⁵, Paul Brunetta⁶, Frank Buttgereit⁷, Hyon K. Choi⁸, Jean-Francois Dicaire⁹, Jeffrey Gelfand¹⁰, Liam Heaney¹¹, Liz Lightstone¹², Leo Lu¹³, Dedee Murrell¹⁴, Michelle Petri¹⁵, James T. Rosenbaum¹⁶, Kenneth Saag¹⁷, Murray Urowitz¹⁸, Kevin L Winthrop¹⁹ and John H. Stone²⁰, ¹Division of Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ²New Zealand Ministry of Health, New Zealand Ministry of Health, Auckland, New Zealand, ³ARC, Amsterdam, Netherlands, ⁴Department of Paediatric Rheumatology, UCL Institute of Child Health and Great Ormond Street Hospital NHS Foundation Trust, London, United Kingdom, ⁵Psychiatry, UT Southwestern Medical Center, Dallas, TX, ⁶Genentech, Inc., South San Francisco, CA, ⁷Rheumatology and Clinical Immunology, Charité - University Medicine Berlin, Berlin, Germany, ⁸Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁹Pinnacle Inc., Quebec, QC, Canada, ¹⁰Neurology, University of California San Francisco, San Francisco, CA, ¹¹Department of Respiratory Medicine, Queen's University Belfast, Belfast, Ireland, ¹²Department of Medicine, Imperial College London, London, England, ¹³Allergy, Immunology, and Rheumatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ¹⁴Department of Dermatology, University of New South Wales, Sydney, Australia, ¹⁵Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ¹⁶Oregon Health & Science University, Portland, OR, ¹⁷Division of Clinical Immunology and Rheumatology, University of Alabama Birmingham School of Medicine, Birmingham, AL, ¹⁸Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ¹⁹Oregon Health and Sciences University, Portland, OR, ²⁰Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA
Background/Purpose: Glucocorticoids (GC) are associated with substantial treatment morbidity. New immunomodulatory agents offer the possibility of limiting GC exposure. To assess the comparative benefits of…